The role of the RIPK4-NF-κB axis in promoting the invasiveness of urothelial bladder carcinoma, and a promising therapy of delivery of RIPK4 small interfering RNA for bladder cancer, was reported by Jian Ye Liu et al. [11,32]. Here, NFKB1 is linked to bladder transitional cell carcinoma.